Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy

Fengying Wu(Shanghai Sixth People's Hospital), Jianjun Zou(Jiangsu Hengrui Medicine (China)), Yiping Zhang(National Health and Family Planning Commission), Shengxiang Ren(Tongji University), Caicun Zhou(Tongji University), Jiuwei Cui(Jilin University), Yi Hu(Union Hospital), Zhehai Wang(Shandong Tumor Hospital), Jianying Zhou(First Affiliated Hospital Zhejiang University), Ying Cheng(Jilin Province Tumor Hospital), Yunchao Huang(Zhejiang Chinese Medical University), Wei Shi(Jiangsu Hengrui Medicine (China)), Yongqian Shu(Jiangsu Province Hospital), Xiaorong Dong(The University of Melbourne), Jian Fang(Peking University), Qun Chen(Stanford University), Jianhua Chen(Hunan Cancer Hospital), Qiming Wang(Hunan Cancer Hospital), Wei Zhang(Capital Medical University), Xiubao Ren(Tianjin Medical University Cancer Institute and Hospital), Zhiyong He(Albert Einstein College of Medicine), Jun Zhao(Beijing Institute of Technology), Lizhu Lin(First Affiliated Hospital of Guangzhou University of Chinese Medicine), Xiaoyan Lin(Fujian Medical University), Jifeng Feng(Jiangsu Cancer Hospital), Kangsheng Gu(Anhui Medical University), Tao Jiang(Tongji University), Jianhua Shi(Linyi People's Hospital), Xuejuan Bai(Genecast (China)), Tao Zhang(Jiangsu Hengrui Medicine (China)), Yunpeng Liu(Shenyang Institute of Automation), Lejie Cao(University of Science and Technology of China), Gongyan Chen(Harbin Medical University), Yongsheng Wang(Lanzhou University of Technology), Jianhua Chang(Shanghai Medical College of Fudan University), Yun Fan(Chinese Academy of Medical Sciences & Peking Union Medical College), Yueyin Pan(University of Science and Technology of China), Liping Wang(Shihezi University)
癌症：英文版
November 4, 2022
10.1002/cac2.12383
Cited by 20

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k